Malignant Male Reproductive System Neoplasm

Malignant Male Reproductive System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

6,225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,451
Recruiting: 784
Ph III recruiting: 82
Growth YoY: +24.4%
Industry share: 18%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 27.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (762)

clinicaltrialsPublishedShowing 51–57 of 57 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04691804	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer	active not recruiting	Phase 3	496	Jiangsu HengRui Medicine Co., Ltd.INDUSTRY	13	Dec 31, 2024	clinicaltrials
NCT06465914	A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males	active not recruiting	Phase 3	9,000	Shanghai Bovax Biotechnology Co., Ltd.